Authors
Latest:
Your new competition...It's not who you think it isDemands on physicians aren't just coming from reps.
Latest:
In Establishing the Evidence Base, He Made Science CountRobert Seidman, Former Chief Pharmacy Officer, Wellpoint
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
New Gains for PainThe global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.
Latest:
The Rise and Fall of Pharma ReputationsAs a reputation driver, ethical behavior has increased steadily in importance over the last three years.
Latest:
Direct to Consumer: HIV and AdherenceThe flaw lies not in the lack of patient information, but rather in the way they process it.
Latest:
BioTech's New Business ModelCoined in the early 1940s, the hybrid term "biotech" has sustained its save-the-world aura and futurist allure. During the industry's nascent years, Amgen, Genentech, and other barrier-breaking companies were mere fledgling operations with products still in the pure science phase and their only "revenue" the hope of curing some of the world's ills.
Latest:
Also Known As...The Value of Generic NamesIn the world of pharmaceutical names, the trademark has always been the star, and every other word has played a supporting role. But recent developments at FDA-and the industry's response to those developments-have set the stage for a new approach to nomenclature.
Latest:
Key Opinion Leaders Interactions with PharmaData suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
Latest:
Pfizer Can Mold Its Future by Learning from the PastPfizer Chairman and CEO Hank McKinnell sees the company's $58 billion blockbuster acquisition of Pharmacia as the key to Pfizer's leadership in pharmaceutical markets around the globe.
Latest:
Beyond TrainingHow to Hire the Right Reps, Train Them to Excel, and Retain Them for the Long Run
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
Predicting Success: A Pipeline ReportMuch has been said about pharma's R&D lag, but a closer look at the candidates currently in Phase III shows that what the pipeline lacks in quantity it makes up for in quality. This Pharmaceutical Executive pipeline report identifies some of the top candidates in five categories: women's health, oncology, central nervous system (CNS), cardiovascular disease (CVD), and metabolic/ endocrine diseases.
Latest:
The Pivotal PrescribersThanks to managed care's efforts to steer patients into the least intensive treatment settings, primary care practitioners (PCPs) play an increasingly important role in prescribing.
Latest:
Generics Battle Heats UpThe competition for generics' 180-day marketing exclusivity is fierce, and Dr. Reddy's Laboratories filed the first court case calling into question FDA's methods for determining exclusivity on a patent-by-patent basis.
Latest:
PE's annual Media Spend TrendsThe economy may still be suffering from the twin shocks of September 11th and a bursting technology bubble, but pharma spending on promotions continues to grow at a double-digit pace.
Latest:
Understanding physician stress (Part Two)Understanding physician stressors and the behavior that follows is one key to enhancing relationships.
Latest:
Canaries in the Coal MineMSL programs were a technical outgrowth of sales, but they have since evolved to partake in field-based clinical and educational efforts for companies’ products. However, in many pharma companies, that evolution has not gone far enough. Companies still continue to focus MSL activities on pushing information out rather than pulling it in from the field and integrating it into their decision-making processes. As such, companies are missing the opportunity to leverage MSLs within a sensory web.
Latest:
Pharma WANTS YOUWhen it comes to recruiting and enrolling individuals in clinical trials, the industry's challenge is similar to the one that General Riggs cites in his call to modernize the US Army.
Latest:
A Better Way to Manage the PipelineA major unresolved issue for the pharmaceutical industry in the 21st century is that few, if any, optimization techniques have found their way into the research portfolio arena.
Latest:
Surviving Career TransitionsPharma is finally feeling the ill effects of the US economic downturn. In response, many companies are restructuring and downsizing. But pharma industry professionals are well positioned to take advantage of many avenues of employment, including other industries, entrepreneurial ventures, and consulting.
Latest:
Public AccessWhen people ask how health seekers look and act on the Web, there's no one answer: The online universe has become just as diverse as the rest of the world. Nowhere is this more evident than in the latest e-health statistics that, when taken together, paint a picture of customers who are beginning to find their feet-and new finesse-online.
Latest:
Networked PharmaDuring the next ten years, big pharma companies will need to launch two products a year to generate 5 percent annual growth, five products a year to hit 10 percent growth, and nine products a year to meet a 15 percent annual growth target. Clearly, the stakes are high.
Latest:
Upgrading to a PDAYour paper planner is full to bursting. Maybe it's time to simplify your life with a personal digital assistant.
Latest:
Know When to BailEmployees in the pharma industry, who once expected lifetime employment, now find themselves facing some of the same dilemmas, including job insecurity and declining stock values, as those in beleaguered industries such as defense and finance. The pharma industry has seen more than its fair share of mergers and acquisitions, and employees increasingly question whether they have a future within their company. Those who make the hiring decisions for large pharma companies say such doubts are reasonable in the current climate and that an honest self-assessment of a variety of factors, including faith in management, opportunity for growth, and job
